Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
Status:
Completed
Trial end date:
2021-08-06
Target enrollment:
Participant gender:
Summary
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose,
phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.